Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
about
The choreography of HIV-1 proteolytic processing and virion assemblyLack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 proteaseABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitorDPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variantsIn vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl proteaseIn vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitorsAntiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorAntiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus proteaseGenetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorImpaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitorsA mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389AS-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapyHigh-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay.Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesA bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 proteaseEfficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisDrug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detectionClinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.Metabolomic screening and identification of the bioactivation pathways of ritonavirInterplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivityIn vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term cultureAttenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.Virus dynamics and drug therapyStructure of equine infectious anemia virus proteinase complexed with an inhibitor.Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease
P2860
Q27009643-97C0A7AA-54EC-4781-810C-4C4A208A3E6CQ27637329-4C201485-DD41-49AD-9619-7B478E0728D2Q27729982-795D090A-3E8F-4105-995B-295DF25E870EQ28344594-6D93BE09-570A-4A69-8980-9B98001645D8Q28344884-4F5B6D15-CEE4-4CAF-8F20-299EBEA0331AQ28361560-6FEA837F-2FC6-40E9-BEEE-448CC285F6DDQ28367941-ACD5C1A4-4032-41AC-8003-B07EDF0BD87EQ28368369-0BED20E2-3B67-42F7-8BDA-A7F548EF57DCQ28369030-0D710029-DD45-4173-BE5E-3955557ECA9BQ28378853-B31C284E-7E07-494D-B2B8-FF722A7BF67DQ28378892-5ED447EA-D3D7-40DF-8D8B-EF75CB132A6AQ28379166-3810C1ED-CFCA-45AC-9CA8-F90465889149Q28379356-590ABA2E-3615-44D1-97A1-0DD204CF93B8Q28379411-7F33231F-C9C9-4E66-9C07-9CC4F6A7DE12Q28379487-036B9C88-6BDE-4D71-A729-B9F74C0BC480Q28379544-D579576F-1586-4209-B75E-F8B8C88E88E2Q30818137-6A2E570A-C52B-4A11-A73D-CFBF114251C5Q33784635-B431AE20-B584-4C68-9B12-53E0834F5232Q33796791-180A89F9-1827-4785-BD51-E00E60DEE30DQ33804495-3CC8DA3D-CD1B-4958-927A-E2E2FC2919CAQ33843999-FE51F137-F0E7-42A4-A0A9-62652ABBCCAAQ33935276-DF59263D-E8E8-4F2C-BBC5-952C2E526B26Q33979321-45701DFB-7490-4760-BF6E-40644A64B9A5Q34005107-88F9B332-D0E5-484D-B8A9-7ECBFEDA24A4Q34010283-14BCC5CE-BCE6-4EF3-BC31-B3587B9E20C6Q34012585-B195F380-28ED-4EB4-9306-2F5B0999869EQ34113737-6123DAF1-7B8E-4F7C-911B-642760949FA6Q34454630-894A9901-26E0-4D48-A8B9-1F8D42A8824BQ35129066-3BAE2E9C-DDD1-49DE-BEEF-8DB3390F06B0Q35369891-CD766318-1E8A-447E-B489-C258055D48F2Q35560481-79136984-AFC2-440E-A2DB-FAD36BF52232Q35626853-7370ED15-A3F0-4027-9ACF-7796974B6C71Q35689381-46455671-65D1-44A0-9E58-89945089C7EFQ35857907-B4CA921E-0684-4887-AEE9-4255903D98DAQ35863619-872D1651-4B1E-4DE1-ADE3-5CFC7001AA28Q35899105-913FB43B-ABC9-4D61-AEF4-67DEE286FF9AQ36244920-B3958FD1-CCD7-402A-8077-187AA291E12BQ36280005-52D40B79-3B2A-4B8C-B510-78BA3B67DB22Q36538695-465369BA-BB08-4465-8AC9-D907D5DE1F6CQ36639502-F57B017C-D7E1-4933-8E0D-4A5B03935DEB
P2860
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Selection and analysis of huma ...... 38, a novel protease inhibitor
@ast
Selection and analysis of huma ...... 38, a novel protease inhibitor
@en
Selection and analysis of huma ...... 38, a novel protease inhibitor
@nl
type
label
Selection and analysis of huma ...... 38, a novel protease inhibitor
@ast
Selection and analysis of huma ...... 38, a novel protease inhibitor
@en
Selection and analysis of huma ...... 38, a novel protease inhibitor
@nl
prefLabel
Selection and analysis of huma ...... 38, a novel protease inhibitor
@ast
Selection and analysis of huma ...... 38, a novel protease inhibitor
@en
Selection and analysis of huma ...... 38, a novel protease inhibitor
@nl
P2093
P2860
P1433
P1476
Selection and analysis of huma ...... 38, a novel protease inhibitor
@en
P2093
D W Norbeck
J W Erickson
M Markowitz
P2860
P304
P407
P577
1995-02-01T00:00:00Z